舌下特异性免疫疗法治疗变应性鼻炎和/或过敏性哮喘的安全性研究  

Safety of sublingual immunotherapy to the patients with allergic rhinitis and/or allergic asthma

作　　者：陈洪[1] 林强[2] 陈平[1] 

机构地区：[1]福建省立医院耳鼻喉科,福州350001 [2]福建省立医院干部二科,福州350001

出　　处：《福建医药杂志》2011年第6期12-14,共3页Fujian Medical Journal

摘　　要：目的探讨舌下特异性免疫疗法治疗变应性鼻炎和过敏性哮喘的安全性。方法对182名过敏性鼻炎和/或过敏性哮喘患者,采用舌下特异性免疫疗法和对症用药相结合的方式进行免疫治疗;跟踪并统计在免疫治疗过程中患者产生的不良反应及其严重程度。结果没有患者出现全身性的不良反应,轻中度不良反应的总发生率为8.24%;14岁以下的患者出现不良反应的比例高于14岁以上的患者。结论舌下特异性免疫治疗引起的不良反应都只是轻中度的,它是一种高安全性的免疫治疗方法。Objective To discuss the safety of sublingual immunotherapy（SLIT）to the patients with allergic rhinitis and/or allergic asthma.Methods One hundred and eighty-two patients with allergic rhinitis and/or allergic asthma were treated with routine medical and Dermatophagoides farinae drops.All the adverse reactions and severity of those were analyzed.Results None serious adverse reaction was reported in this study.8.24% of the patients appeared mild-to-moderate adverse reactions.In addition,incidence of adverse reaction in patients under 14 years old were higher than that in patients over 14 years old.Conclusion Only mild or moderate adverse reactions were reported in patients treated with SLIT.This study appears to provide further evidence that SLIT is a high-safety administration route of immunotherapy.

关 键 词：舌下特异性免疫治疗 安全性 不良反应 

分 类 号：R765.21[医药卫生—耳鼻咽喉科] R453.9[医药卫生—临床医学]